Newer Therapeutics to Selectively Kill

Abstract readReview

In one paragraph

Review in Infectious disease reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Microbiome-based therapeutics forGut microbes · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Guido GranataSystemic and Immune Depression-Associated Infection Unit, National Institute for Infectious Diseases "L. Spallanzani", I.R.C.C.S., 00149 Roma, Italy.ORCID 0000-0001-5796-0545

Nicola PetrosilloInfectious Disease Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00127 Rome, Italy.ORCID 0000-0002-2585-7567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe antibiotic ibezapolstat and the live biotherapeutic product live-JSLM are promising future approaches for treating

methodsData sources: PubMed and SCOPUS databases were searched from 1 January 2012 to 15 November 2025. Original articles reporting data on ibezapolstat and live-JSLM were included.

results31 studies were included. When compared to conventional anti-

conclusionsThe results on ibezapolstat efficacy are promising, but require confirmation in larger patient populations through double-blind, randomised phase III trials. In the near future, an integrated approach may enhance the management of

Indexed as

bile acidsclinical trialsClostridioides difficile infection managementfaecal microbiota transplantationhuman gut microbiotaibezapolstatlive biotherapeutic productlive-JSLMlong term patients’ outcomemicrobiome-based therapiesnovel antimicrobialsprevention of recurrence of Clostridioides difficile infectionquality of lifeRebyota

Identifiers

PMID42042323

DOI10.3390/idr18020034

PMCPMC13116874

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.